NYSE: ECLEcolab Inc Stock
$246.91+7.88 (+3.3%)
Updated Apr 29, 2025
ECL Price
$246.91
Fair Value Price
N/A
Market Cap
$69.87B
52 Week Low
$220.96
52 Week High
$273.69
P/E
33.23x
P/B
7.98x
P/S
4.23x
PEG
4.54x
Dividend Yield
0.99%
Revenue
$15.74B
Earnings
$2.11B
Gross Margin
43.5%
Operating Margin
18%
Profit Margin
13.4%
Debt to Equity
1.55
Operating Cash Flow
$3B
Beta
0.93
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ECL Overview
Ecolab Inc. offers water treatment and purification services, technology and systems used by public utilities and private companies to treat water for drinking and use in food, healthcare, and hospitality applications. Known as Economics Laboratory until 1986, Ecolab was founded and is headquartered in Saint Paul, MN.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ECL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Specialty Chemical
Industry Rating
C
ECL
Ranked#27 of 52
Ranked#27 of 52
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $33.03 | A | |
| $42.00 | B | |
| $10.24 | B |
Be the first to know about important ECL news, forecast changes, insider trades & much more!
ECL News
Overview
Due Diligence Score
–
Industry Average (36)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ECL scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ECL ($246.91) is trading above its intrinsic value of $60.94, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ECL is poor value based on its earnings relative to its share price (33.23x), compared to the US market average (29.19x)
P/E vs Market Valuation
ECL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more ECL due diligence checks available for Premium users.
Valuation
ECL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
33.23x
Industry
27.8x
Market
29.19x
ECL is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ECL is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
ECL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
7.98x
Industry
3.18x
ECL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ECL price to earnings growth (PEG)
For valuing profitable companies with growth potential
ECL is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
ECL's financial health
Profit margin
Revenue
$4.0B
Net Income
$472.9M
Profit Margin
11.8%
ECL's Earnings (EBIT) of $2.83B... subscribe to Premium to read more.
Interest Coverage Financials
ECL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$22.4B
Liabilities
$13.6B
Debt to equity
1.55
ECL's short-term assets ($6.03B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ECL's long-term liabilities ($8.81B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ECL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ECL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$766.7M
Investing
-$627.5M
Financing
-$140.1M
ECL's operating cash flow ($2.81B)... subscribe to Premium to read more.
Debt Coverage Financials
ECL vs Specialty Chemical Stocks
Ecolab Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.